KR101479537B1 - 항-ｉｌ-6 모노클로날 항체 및 이의 용도 - Google Patents

항-ｉｌ-6 모노클로날 항체 및 이의 용도 Download PDF

Info

Publication number
KR101479537B1
KR101479537B1 KR20097003512A KR20097003512A KR101479537B1 KR 101479537 B1 KR101479537 B1 KR 101479537B1 KR 20097003512 A KR20097003512 A KR 20097003512A KR 20097003512 A KR20097003512 A KR 20097003512A KR 101479537 B1 KR101479537 B1 KR 101479537B1
Authority
KR
South Korea
Prior art keywords
seq
cdr3
cdr2
cdr1
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR20097003512A
Other languages
English (en)
Korean (ko)
Other versions
KR20090039801A (ko
Inventor
에르네스트 에스. 스미쓰
웨이 왕
Original Assignee
백시넥스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 백시넥스 인코포레이티드 filed Critical 백시넥스 인코포레이티드
Publication of KR20090039801A publication Critical patent/KR20090039801A/ko
Application granted granted Critical
Publication of KR101479537B1 publication Critical patent/KR101479537B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR20097003512A 2006-08-03 2007-08-03 항-ｉｌ-6 모노클로날 항체 및 이의 용도 Expired - Fee Related KR101479537B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83510706P 2006-08-03 2006-08-03
US60/835,107 2006-08-03
PCT/US2007/017337 WO2008019061A2 (en) 2006-08-03 2007-08-03 Anti-il-6 monoclonal antibodies and uses thereof

Publications (2)

Publication Number Publication Date
KR20090039801A KR20090039801A (ko) 2009-04-22
KR101479537B1 true KR101479537B1 (ko) 2015-01-07

Family

ID=39033490

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20097003512A Expired - Fee Related KR101479537B1 (ko) 2006-08-03 2007-08-03 항-ｉｌ-6 모노클로날 항체 및 이의 용도

Country Status (17)

Country Link
US (1) US7919095B2 (enExample)
EP (1) EP2064241B1 (enExample)
JP (1) JP2009545319A (enExample)
KR (1) KR101479537B1 (enExample)
CN (1) CN101563365B (enExample)
AU (1) AU2007282023B2 (enExample)
BR (1) BRPI0715115A2 (enExample)
CA (1) CA2657763C (enExample)
CO (1) CO6150192A2 (enExample)
CR (1) CR10563A (enExample)
EA (1) EA200900037A1 (enExample)
IL (1) IL196550A0 (enExample)
MA (1) MA30653B1 (enExample)
MX (1) MX2009001110A (enExample)
NO (1) NO20090224L (enExample)
WO (1) WO2008019061A2 (enExample)
ZA (1) ZA200900514B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
SI3187506T1 (sl) 2007-05-21 2019-08-30 Alderbio Holdings Llc Protitelesa proti IL-6 in njihova uporaba
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
ES2564635T3 (es) 2008-05-13 2016-03-28 Novimmune Sa Anticuerpos anti-IL-6/IL-6R y métodos de uso de los mismos
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2010036851A2 (en) * 2008-09-26 2010-04-01 Wyeth Llc Single chain antibody library design
RU2532826C2 (ru) * 2008-11-13 2014-11-10 Фемта Фармасьютикалз, Инк. Гуманизированные антитела против il-6
US8337847B2 (en) * 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
DK3338799T3 (da) * 2008-11-25 2021-06-14 Vitaeris Inc Antistoffer til il-6 og anvendelse deraf
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
EP2504030A4 (en) 2009-11-24 2013-06-26 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
CN106046159B (zh) 2010-03-12 2020-06-16 德彪发姆国际有限公司 Cd37结合分子及其免疫缀合物
EP2643018B1 (en) 2010-11-23 2020-10-14 AlderBio Holdings LLC Anti-il-6 antibodies for the treatment of oral mucositis
US20120189621A1 (en) 2011-01-21 2012-07-26 Yann Dean Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
EP2694105A4 (en) 2011-04-01 2015-04-29 Immunogen Inc CD37 BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF
WO2013175276A1 (en) * 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
AU2013335004B2 (en) 2012-10-22 2018-06-28 Oneness Biotech Co. LTD Antibodies to interleukin-6 and uses thereof
KR102149206B1 (ko) * 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
CA2986437A1 (en) 2015-06-08 2016-12-15 Debiopharm International, S.A. Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
EA201890185A1 (ru) 2015-07-31 2018-07-31 Медиммун Лимитед Способы лечения опосредованных гепсидином нарушений
WO2017040247A1 (en) 2015-08-28 2017-03-09 Immunogen, Inc. Antibodies and assays for detection of cd37
EA201891732A1 (ru) * 2016-02-02 2019-02-28 Кадмон Корпорейшн, Ллк Биспецифичные связывающие белки для pd-l1 и kdr
KR20230058733A (ko) * 2016-05-05 2023-05-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체
WO2018083633A1 (en) 2016-11-02 2018-05-11 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
MX2020006882A (es) 2018-01-05 2020-09-07 Novo Nordisk As Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion.
MX2020012755A (es) 2018-05-30 2021-02-26 Debiopharm Int Sa Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37).
CN109517064B (zh) * 2018-10-10 2020-05-08 北京汇智和源生物技术有限公司 白介素-6的人源化单克隆抗体、其编码基因及应用
EP3986481A2 (en) 2019-06-20 2022-04-27 Takeda Pharmaceutical Company Limited Method of treatment with viral-based gene therapy
CN112279913B (zh) * 2020-10-30 2022-05-03 上海百英生物科技有限公司 一种抗人il-6单克隆抗体及应用
CA3203308A1 (en) 2020-11-30 2022-06-02 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
CN115925792B (zh) * 2022-08-19 2025-06-27 浙江农林大学 一种香榧活性肽及其在制备降血压产品中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2598666B2 (ja) * 1987-10-19 1997-04-09 忠三 岸本 抗ヒトｂｃｄｆモノクローナル抗体
IL88375A (en) * 1988-11-14 1995-07-31 Yeda Res & Dev Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method
ATE102631T1 (de) * 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
EP0399429A1 (en) * 1989-05-22 1990-11-28 Toray Industries, Inc. Anti-human interleukin-6 monoclonal antibody
JPH03139292A (ja) * 1989-05-22 1991-06-13 Toray Ind Inc ヒトインタ―ロイキン―６に対するモノクロ―ナル抗体
JP2881311B2 (ja) 1989-07-28 1999-04-12 味の素株式会社 抗ヒトｂｃｄｆモノクローナル抗体及びそれを用いたヒトｂｃｄｆの定量法
DE3939706C1 (enExample) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5856135A (en) * 1993-05-31 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6
JP3614183B2 (ja) * 1993-05-31 2005-01-26 中外製薬株式会社 ヒトインターロイキン−６に対する再構成ヒト抗体
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
CA2168963C (en) * 1994-06-07 2007-01-16 Masayuki Miyata Drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the lung and model animals of the diseases
CA2201781C (en) 1994-10-07 2010-01-12 Tadamitsu Kishimoto Chronic rheumatoid arthritis therapy containing il-6 antagonist as effective component
AU704723B2 (en) * 1994-12-29 1999-04-29 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
JPH10324639A (ja) * 1997-03-21 1998-12-08 Chugai Pharmaceut Co Ltd Ｉｌ−６アンタゴニストを有効成分として含有する感作ｔ細胞関与疾患の予防・治療剤
JP4124573B2 (ja) 1998-03-17 2008-07-23 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する炎症性腸疾患の予防又は治療剤
US7494652B1 (en) 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
CA2341239C (en) 1998-08-24 2011-01-04 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
AU2736400A (en) * 1999-01-27 2000-08-18 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
JP2003531867A (ja) * 2000-05-03 2003-10-28 メディミューン，インコーポレイテッド 抗体および抗炎症薬を用いた呼吸器疾患の組合せ治療法
EP1334731B1 (en) * 2000-10-25 2008-02-27 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
JP4889187B2 (ja) * 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
ATE352040T1 (de) * 2000-11-17 2007-02-15 Univ Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
MXPA03007878A (es) * 2001-03-02 2004-07-08 Medimmune Inc Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina.
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
PT2308888T (pt) * 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
US20050037358A1 (en) * 2001-12-21 2005-02-17 Serge Muyldermans Method for cloning of variable domain sequences
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
AU2003261787B2 (en) * 2002-08-30 2008-11-06 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of the antibody
WO2004045507A2 (en) 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
WO2004071404A2 (en) * 2003-02-04 2004-08-26 Centocor Inc. Use of il-6 antagonists in combination with steroids to enhance apoptosis
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
NZ541928A (en) 2003-02-24 2009-06-26 Chugai Pharmaceutical Co Ltd Remedy for spinal injury containing interleukin-6 antagonist
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005023193A2 (en) 2003-09-04 2005-03-17 Interleukin Genetics, Inc. Methods of treating endometriosis
CA2543779A1 (en) * 2003-10-24 2005-05-06 Medtronic, Inc. Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators
US20050100550A1 (en) * 2003-11-10 2005-05-12 Mohit Trikha Anti-angiogenic uses of IL-6 antagonists
DE602005020743D1 (de) 2004-02-11 2010-06-02 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
US20060177436A1 (en) 2004-12-16 2006-08-10 Genentech, Inc. Methods for Treating Autoimmune Disorders
US20060228416A1 (en) * 2005-04-06 2006-10-12 Marie-Pierre Faure Methods for modulating topical inflammatory response
EP1712241A1 (en) 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
EP2377884A1 (en) 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Molecular Immunology, Vol. 28, No. 11, pp. 1155-1161, 1991 *
Molecular Immunology, Vol. 28, No. 11, pp. 1183-1192, 1991 *

Also Published As

Publication number Publication date
CN101563365A (zh) 2009-10-21
WO2008019061A2 (en) 2008-02-14
AU2007282023B2 (en) 2012-09-13
US7919095B2 (en) 2011-04-05
EA200900037A1 (ru) 2009-10-30
CR10563A (es) 2009-04-14
MX2009001110A (es) 2009-05-11
US20080075726A1 (en) 2008-03-27
NO20090224L (no) 2009-03-31
CO6150192A2 (es) 2010-04-20
KR20090039801A (ko) 2009-04-22
WO2008019061A3 (en) 2008-10-09
CA2657763A1 (en) 2008-02-14
EP2064241A2 (en) 2009-06-03
CA2657763C (en) 2016-05-31
CN101563365B (zh) 2012-10-31
JP2009545319A (ja) 2009-12-24
BRPI0715115A2 (pt) 2013-06-04
MA30653B1 (fr) 2009-08-03
IL196550A0 (en) 2011-08-01
EP2064241B1 (en) 2015-10-07
ZA200900514B (en) 2010-04-28
AU2007282023A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
KR101479537B1 (ko) 항-ｉｌ-6 모노클로날 항체 및 이의 용도
CN109414455B (zh) Bcma结合分子及其使用方法
CN1849138B (zh) 作为选择性ngf途径抑制剂的人抗ngf中和抗体
US6312693B1 (en) Antibodies against human CD40
KR101317045B1 (ko) 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
KR20100035643A (ko) 성숙 수지상 세포에서의 허용유발 표현형의 유도
CN1849339A (zh) 治疗性结合分子
HU227217B1 (en) Immunoglobulin variants and uses thereof
AU2004272289B2 (en) Therapeutic binding molecules
KR20210068065A (ko) 안타고니스트
KR20060022646A (ko) Ｓｔｏｐ-1 관련 조성물 및 방법
US20170073391A1 (en) Osteoprotegerin derived RANKL inhibitor
EA034861B1 (ru) Композиция, полученная из остеопротегерина, и способ ее использования
WO2025167705A1 (zh) 一种抗tl1a抗体及其制备方法和用途
MXPA06003128A (en) Therapeutic binding molecules
WO2014168715A1 (en) B7 ligands/cd20 inhibitor composition and use thereof
KR20070022045A (ko) 장애의 치료
HK1096310B (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20171213

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20181231

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20181231